Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

Phase III Studies

Tigecycline (Tygacil®): effective in the treatment of complicated intra-abdominal infections1

The efficacy of Tygacil for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data1

Data from two randomised, double-blind, active-controlled, multi-national, multi-centre studies of 1642 adult patients. Tygacil 100 mg was given as initial dose, followed by 50 mg every 12 hours for up to 14 days. Imipenem/cilastatin 500 mg/500 mg was given every 6 hours for 5 to 14 days.1

Single-agent efficacy comparable to imipenem/cilastatin in cIAI adults1

Full preview Percentage of patients who achieved clinical care

Patients who achieved clinical cure* (%)

Adapted from Babinchak et al. 2005.1

*Among microbiologically evaluable patients at the TOC visit (12-42 days after therapy): 95% CI for the differences. -4.5% to 4.4% (P<0.0001 for non-inferiority). 
Cure = the course of study drug and initial intervention (operative and/or radiographically controlled drainage procedure) resolved the intra-abdominal infection.

Cure rates by clinical diagnosis in cIAI at test of cure in the microbiologically evaluable mITTpopulation1

Full preview Cure rates by clinical diagnosis

Adapted from Babinchak et al. 20051

View complicated intra-abdominal infections (cIAI) European real-life data

Read More

References

  1. Babinchak T, Ellis-Grosse E et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41 Suppl 5:S354-367